Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected sales and profit growth at the lower end of its guidance this year.

The Ozempic ma

📰

Continue Reading on The Irish Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →